Payment overview · 2025
General Payments
$1,357.95
61 reported records · 17 companies
Healthcare provider profile · identity verified
Corwin Ashford Thomas, D.O.
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · LAFAYETTE, LA · NPI 1013920362
Verified facts
What the public records show
CMS Open Payments records show Corwin Ashford Thomas, D.O. received $1,357.95 in general payments during 2025 across 61 reported records.
ABIOMED accounted for 27.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Kerendia, Verquvo.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 136 claims for Kerendia by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLIZET as an associated drug or biological on 63 records involving 47 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Nexlizet by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VERQUVO as an associated drug or biological on 38060 records involving 12268 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Verquvo by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABIOMED | Unresolved — no canonical attribution shown | $373.77 | 27.5% | 12 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $161.18 | 11.9% | 10 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $138.29 | 10.2% | 7 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $111.23 | 8.2% | 6 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $104.44 | 7.7% | 6 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $87.39 | 6.4% | 4 | 2025 |
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $85.20 | 6.3% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $71.82 | 5.3% | 4 | 2025 |
| Kestra Medical Technology Services, Inc. | Unresolved — no canonical attribution shown | $42.67 | 3.1% | 1 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $38.96 | 2.9% | 1 | 2025 |
| Bard Peripheral Vascular, Inc. | Unresolved — no canonical attribution shown | $34.07 | 2.5% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $22.52 | 1.7% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $19.07 | 1.4% | 1 | 2025 |
| Chiesi USA, Inc. | Unresolved — no canonical attribution shown | $18.04 | 1.3% | 1 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $17.52 | 1.3% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $16.94 | 1.2% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.84 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,357.95 | 61 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $161.18 | 10 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $138.29 | 7 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $97.28 | 5 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $87.39 | 4 | 2025 |
Source payment records
|
|||||
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $85.20 | 3 | 2025 |
Source payment records
|
|||||
| DIAMONDBACK CORONARY Normalized: diamondback coronary |
Device | Abbott Laboratories | $55.18 | 3 | 2025 |
Source payment records
|
|||||
| Assure WCD Normalized: assure wcd |
Device | Kestra Medical Technology Services, Inc. | $42.67 | 1 | 2025 |
Source payment records
|
|||||
| Hillrom - Carnation Ambulatory Monitor Normalized: hillrom carnation ambulatory monitor |
Device | Baxter Healthcare | $38.96 | 1 | 2025 |
Source payment records
|
|||||
| Venovo Normalized: venovo |
Device | Bard Peripheral Vascular, Inc. | $34.07 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $22.52 | 1 | 2025 |
Source payment records
|
|||||
| Eagle Eye Normalized: eagle eye |
Device | Philips North America LLC | $22.52 | 1 | 2025 |
Source payment records
|
|||||
| Rubicon 18 Normalized: rubicon 18 |
Device | Boston Scientific Corporation | $19.94 | 1 | 2025 |
Source payment records
|
|||||
| ZelanteDVT ClotHunter Normalized: zelantedvt clothunter |
Device | Boston Scientific Corporation | $19.16 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $19.07 | 1 | 2025 |
Source payment records
|
|||||
| JUXTAPID Normalized: juxtapid |
Drug | Chiesi USA, Inc. | $18.04 | 1 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $17.52 | 1 | 2025 |
Source payment records
|
|||||
| General - Catheters Normalized: general catheters |
Device | Boston Scientific Corporation | $17.18 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $16.94 | 1 | 2025 |
Source payment records
|
|||||
| MOMENTUM EL ICD VR Normalized: momentum el icd vr |
Device | Boston Scientific Corporation | $16.92 | 1 | 2025 |
Source payment records
|
|||||
| ESPRIT Normalized: esprit |
Device | Abbott Laboratories | $16.64 | 1 | 2025 |
Source payment records
|
|||||
| General - Guidewires Normalized: general guidewires |
Device | Boston Scientific Corporation | $15.83 | 1 | 2025 |
Source payment records
|
|||||
| Ranger Normalized: ranger |
Device | Boston Scientific Corporation | $15.41 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $14.84 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Kerendia kerendia |
2025 | Kerendia | 2024 | 136 | exact normalized | Medicare Part D |
| VERQUVO verquvo |
2025 | Verquvo | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
136 | 37 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLIZET open payments reported associated product |
CMS Open Payments — General Payments 63 supporting records · 47 recipient NPIs · example record 1243951667 |
Nexlizet · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | VERQUVO open payments reported associated product |
CMS Open Payments — General Payments 38060 supporting records · 12268 recipient NPIs · example record 1237992208 |
Verquvo · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
82 | 27 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Clopidogrel | Clopidogrel Bisulfate | 968 | 275 |
| Ranolazine Er | Ranolazine | 478 | 121 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 471 | 147 |
| Xarelto | Rivaroxaban | 447 | 121 |
| Metoprolol Succinate | Metoprolol Succinate | 363 | 109 |
| Atorvastatin Calcium | Atorvastatin Calcium | 346 | 115 |
| Eliquis | Apixaban | 261 | 61 |
| Pravastatin Sodium | Pravastatin Sodium | 245 | 63 |
| Carvedilol | Carvedilol | 234 | 64 |
| Pantoprazole Sodium | Pantoprazole Sodium | 219 | 62 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 209 | 71 |
| Amlodipine Besylate | Amlodipine Besylate | 197 | 64 |
| Ezetimibe | Ezetimibe | 188 | 68 |
| Testosterone Cypionate | Testosterone Cypionate | 186 | 57 |
| Entresto | Sacubitril/Valsartan | 163 | 41 |
| Losartan Potassium | Losartan Potassium | 159 | 48 |
| Nebivolol Hcl | Nebivolol Hcl | 149 | 48 |
| Vascepa | Icosapent Ethyl | 143 | 42 |
| Kerendia | Finerenone | 136 | 37 |
| Cilostazol | Cilostazol | 130 | 42 |
| Furosemide | Furosemide | 109 | 30 |
| Levothyroxine Sodium | Levothyroxine Sodium | 104 | 32 |
| Digoxin | Digoxin | 103 | 26 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 100 | 31 |
| Nitroglycerin | Nitroglycerin | 88 | 46 |
| Glimepiride | Glimepiride | 85 | 35 |
| Lisinopril | Lisinopril | 82 | 25 |
| Metformin Hcl | Metformin Hcl | 82 | 27 |
| Ozempic | Semaglutide | 82 | 27 |
| Jardiance | Empagliflozin | 80 | 17 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 72 | 28 |
| Famotidine | Famotidine | 60 | 14 |
| Sotalol | Sotalol Hcl | 58 | 14 |
| Brilinta | Ticagrelor | 56 | 18 |
| Clonidine | Clonidine | 53 | 13 |
| Farxiga | Dapagliflozin Propanediol | 51 | 17 |
| Repatha Sureclick | Evolocumab | 51 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 49 | 13 |
| Potassium Chloride | Potassium Chloride | 48 | 21 |
| Icosapent Ethyl | Icosapent Ethyl | 45 | 29 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 45 | 18 |
| Prasugrel Hcl | Prasugrel Hcl | 41 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 41 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 38 | suppressed |
| Gabapentin | Gabapentin | 37 | 13 |
| Methylprednisolone | Methylprednisolone | 37 | 23 |
| Glipizide | Glipizide | 36 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 35 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 33 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 32 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 31 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 31 | 11 |
| Simvastatin | Simvastatin | 31 | suppressed |
| Verquvo | Vericiguat | 31 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 28 | suppressed |
| Zontivity | Vorapaxar Sulfate | 28 | 15 |
| Torsemide | Torsemide | 27 | 11 |
| Mounjaro | Tirzepatide | 25 | 14 |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 23 | 19 |
| Allopurinol | Allopurinol | 22 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 22 | suppressed |
| Diazepam | Diazepam | 22 | 15 |
| Spironolactone | Spironolactone | 22 | suppressed |
| Glipizide Er | Glipizide | 21 | suppressed |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Metolazone | Metolazone | 20 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Praluent Pen | Alirocumab | 16 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 16 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 15 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | 15 |
| Linzess | Linaclotide | 15 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Evkeeza | Evinacumab-Dgnb | 13 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Sotalol Af | Sotalol Hcl | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Meloxicam | Meloxicam | 11 | suppressed |
| Nadolol | Nadolol | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,357.95 · 61 records | ABIOMED | Assure WCD, CAPVAXIVE, DIAMONDBACK CORONARY, ESPRIT, Eagle Eye, General - Catheters, General - Guidewires, Hillrom - Carnation Ambulatory Monitor, INSPIRE, JUXTAPID, Kerendia, LifeVest, MOMENTUM EL ICD VR, NEXLETOL, OPSUMIT, REPATHA, Ranger, Rubicon 18, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, VERQUVO, Venovo, Wegovy, ZelanteDVT ClotHunter | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Kerendia play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Bayer Healthcare Pharmaceuticals Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error